ArticleslgStudy

chemistry

LY-2624803

LY-2624803 is a chemistry topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand LY-2624803 rather than just read about it. In short: LY-2624803, also known as HY-10275, is a dual histamine H1 receptor and serotonin 5-HT2A receptor antagonist which was under development for the treatment of insomnia but was never marketed. It is taken orally.

LY-2624803 — main illustration
LY-2624803 — illustration

Key takeaways

  • LY-2624803 belongs to chemistry; place it in that map before memorising details.
  • Learn the definition first, then one example that makes the definition concrete.
  • Connect LY-2624803 to a quantity you can measure, compute or draw — that is where exam questions come from.
  • Reproduce the core statement of LY-2624803 from memory before moving on to harder problems.

Reference excerpt

LY-2624803, also known as HY-10275, is a dual histamine H1 receptor and serotonin 5-HT2A receptor antagonist which was under development for the treatment of insomnia but was never marketed. It is taken orally.

Pharmacology The drug is described as a high-affinity highly selective histamine H1 receptor inverse agonist with additional strong serotonin 5-HT2A receptor antagonism or inverse agonism. The precise balance of these activities has not been disclosed. It was found to dose-dependently increase slow wave sleep in animals. In a phase 2 clinical trial, the drug was found to significantly reduce wake after sleep onset (WASO) (by 35 minutes at 1 mg and by 62 minutes at 3 mg) as well as to reduce sleep onset latency in humans. No next-day residual fatigue was observed. In terms of chemical structure, it is an analogue of tricyclic compounds like quetiapine and amoxapine.

Development LY-2624803 was under development by Eli Lilly and Hypnion. Its development was discontinued in 2011. The drug reached phase 2 trials prior to the discontinuation of its development. Besides doxepin (Silenor; SO-101) and esmirtazapine (ORG-50081), it was one of the only histamine H1 receptor antagonists to have reached phase 2 trials for treatment of insomnia.

See also Serotonin 5-HT2A receptor antagonist List of investigational insomnia drugs

References

Illustrations

LY-2624803 illustration

Worked examples

Example 1 — a first encounter with LY-2624803

Start with the simplest possible case. Write down what LY-2624803 claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In chemistry, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to LY-2624803 before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about LY-2624803 ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of LY-2624803

In research
LY-2624803 appears in chemistry research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry
Engineering practice reuses LY-2624803 in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom
LY-2624803 is common in secondary-school and first-year university syllabi. It links to neighbouring topics 5-HT2A antagonists, Abandoned drugs, Benzoxazepines, so understanding it makes those chapters shorter.
In everyday life
Look for LY-2624803 outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.
Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “LY-2624803” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study LY-2624803 in 20 minutes

  1. Read the reference excerpt below once, without taking notes.
  2. Close the page and write down what LY-2624803 means in your own words.
  3. Compare your version with the excerpt and mark what you missed.
  4. Work through the three examples above with pen and paper.
  5. Explain LY-2624803 out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is LY-2624803 in simple terms?

LY-2624803, also known as HY-10275, is a dual histamine H1 receptor and serotonin 5-HT2A receptor antagonist which was under development for the treatment of insomnia but was never marketed. It is taken orally.

Why does LY-2624803 matter?

Because it connects several chemistry ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study LY-2624803?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on LY-2624803.

Tags

  • 5-HT2A antagonists
  • Abandoned drugs
  • Benzoxazepines
  • Drugs not assigned an ATC code
  • H1 receptor antagonists
  • Heterocyclic compounds with 3 rings
  • Hypnotics
  • Methyl compounds
  • Piperazines
  • Propionic acids
  • Sedatives

Keep exploring